• August 2021 - JAMA Dermatology 

    According to a study by Blauvelt et al. Published in JAMA Dermatology, upadacitinib demonstrated greater efficacy in patients with moderate to severe atopic dermatitis (AD) than dupilumab.

    Researchers conducted a 24-week, multicenter, phase 3b, randomized, double-blind clinical trial comparing the safety and efficacy of upadacitinib with dupilumab in 692 adults with moderate to severe AD who were candidates for systemic therapy. Patients were randomized to receive oral upadacitinib (30 mg once daily) or dupilumab subcutaneously (300 mg every other week). The primary end point was 75% improvement.

    The study included 348 patients in the upadacitinib arm and 344 patients in the dupliumab arm. There were significantly more patients who reached EASI 75 at week 16 in the upadacitinib-treated group than in the dupilumab-treated group (247 [71.0%] vs 210 [61.1%]). All ranked secondary endpoints showed superiority for upadacitinib.

    Serious adverse events and adverse events leading to drug discontinuation were 2.9% and 2.0% for upadacitinib and 1.2% and 1.2% for dupilumab, respectively.